We describe the prevalence of hepatitis C virus (HCV) infection among noninjection users of heroin in Italy and compare the prevalence of HCV infection among noninjection drug users (NIDUs) and injection drug users (IDUs). Multiple logistic regression analysis of data from NIDUs showed that hepatitis B virus (HBV) infection status was the only independent predictor of HCV seroprevalence. Among IDUs, the number of years of drug use and HBV and human immunodeficiency virus infection status were independent predictors of HCV seropositivity. We found an HCV infection prevalence of 20% among NIDUs. This rate was much lower than that for IDUs, who are 11 times more likely to have antibodies against HCV. The prevalence of HCV infection was much higher than that of HBV infection among the IDUs. In contrast, the prevalence of HBV infection was slightly higher than that of HCV infection among unvaccinated NIDUs. The prevalence of HCV infection among long-term IDUs approached true population saturation; among long-term NIDUs, however, it appeared to plateau at ∼40%. Additional research on HCV infection among NIDUs is needed to develop a strategic prevention program for this patient subgroup.
We describe the prevalence of hepatitis C virus (HCV) infection among noninjection users of heroin in Italy and compare the prevalence of HCV infection among noninjection drug users (NIDUs) and injection drug users (IDUs). Multiple logistic regression analysis of data from NIDUs showed that hepatitis B virus (HBV)
infection status was the only independent predictor of HCV seroprevalence. Among IDUs, the number of years of drug use and HBV and human immunodeficiency virus infection status were independent predictors of HCV seropositivity. We found an HCV infection prevalence of 20% among NIDUs. This rate was much lower than that for IDUs, who are 11 times more likely to have antibodies against HCV. The prevalence of HCV infection was much higher than that of HBV infection among the IDUs. In contrast, the prevalence of HBV infection was slightly higher than that of HCV infection among unvaccinated NIDUs. The prevalence of HCV infection among long-term IDUs approached true population saturation; among long-term NIDUs, however, it appeared to plateau at ∼40%. Additional research on HCV infection among NIDUs is needed to develop a strategic prevention program for this patient subgroup.
Injection drug users (IDUs) constitute the largest group of persons at high risk for acquiring hepatitis C virus (HCV) infection in developed countries [1] [2] [3] . During the past 2 decades, there have been large increases in the numbers of noninjection heroin users in several parts of the world, including the United States [4, 5] and Europe [6] [7] [8] , including Italy. There have been relatively few studies of HCV infection among these noninjection heroin users. These studies have, however, shown substantial prevalence of HCV infection, with prevalence rates of ∼10%-20% [9] [10] [11] . The reasons for these substantial rates are not clear. Sexual transmission involving high-risk sex partners and bloodborne transmission are both possible sources of infection [12] [13] [14] .
Here, we report the prevalence of HCV infection among noninjection drug users (NIDUs) in a large cohort of drug users in northern Italy. We also compare the prevalence of HCV infection among these NIDUs with the prevalence among IDUs recruited from the same sites.
PATIENTS AND METHODS

Study protocol. From February 2001 through August
2001, baseline interviews were conducted with IDUs and NIDUs receiving pharmacological treatment for opiate addiction with methadone, buprenorphine, or naltrexone. Many of these persons also used nonopiate drugs.
Data are from 16 Public Health Authority Centers for Drug Users (PCDUs) in the Veneto region of Italy. All of these centers are part of a regional scientific re- search group dealing with drug problems (abbreviated to GICS). The PCDUs provide counseling; perform laboratory tests for detection of viral hepatitis, HIV, and syphilis; and provide drug abuse chemotherapy, among other things, as described elsewhere [15] . A total of 1095 persons agreed to participate in the study. Patients did not receive any incentive for participating. After the subjects provided informed consent, standardized, faceto-face interviews were performed by doctors and nurses at each center.
Measures.
The interview included questions about sociodemographic characteristics, drug use, and sexual behavior. Drug use-related questions included the age at which the patient started use and the route of drug administration. Injection drug use was defined as any injection of drugs during the patient's lifetime ("Have you ever used drugs by injection?"). Questions regarding current behavior referred to the period of 6 months before the interview.
The analysis of serological status for each patient was part of a routine entry medical examination and was performed at 16 different laboratories associated with the PCDUs. United Biomedical HCV EIAs (Organon Laboratories) were used to detect antibodies to HCV (anti-HCV). Serum samples were analyzed by ELISA for the presence of HIV antibody, and the results were confirmed by Western blot. For the determination of hepatitis B virus (HBV) antibody markers (hepatitis B surface antigen, antibody to hepatitis B surface antigen, and total antibody to hepatitis B core antigen), all laboratories used EIA kits (Abbott Laboratories). The treponema pallidum hemoagglutination test was used to determine markers for syphilis.
Data analyses. An initial analysis of frequency was performed to identify the different characteristics of the 2 groups of drug users. The x 2 test or Fisher's exact test was used to compare categorical variables. Analysis of variance was used to study continuous variables. Bonferroni's correction was applied when multiple comparisons were performed.
Separate analyses were conducted for IDUs and NIDUs to assess the prevalence of HCV infection and associated factors in the 2 groups. Associations between various subject characteristics and anti-HCV status were assessed by x 2 test for cat- meaningful independent predictor of HCV infection status among these NIDUs. Although HIV infection status was found to be significant, the number of NIDUs who were HIV seropositive was too small for interpretation.
Findings of univariate and multivariate analysis of data from IDUs.
Univariate predictors of HCV seropositivity among the IDUs are presented in table 4. Age, duration of drug use, level of education, living situation, having a regular sex partner who is a drug user, and HBV and HIV infection status were all associated with HCV seropositivity among IDUs. In multiple logistic analysis (table 5) , only duration of drug use and HBV and HIV infection status were independent predictors of HCV seropositivity. Figure 1 presents the prevalence of HCV infection among IDUs and NIDUs, according to duration of drug use. Note that the prevalence of HCV infection approaches 100% for longterm IDUs but appears to plateau at ∼40% for long-term NIDUs. 
DISCUSSION
In this study, we found a substantial prevalence of HCV infection (20%) among NIDUs in the 16 PCDUs in the Veneto region of northern Italy. This rate of positivity was high, compared with that for the general population of the same area (3%) [17] , but it was much lower than the prevalence among IDUs, who are 11 times more likely to have anti-HCV. The seroprevalence of HCV infection among NIDUs in our study is toward the lower end of the range of the prevalences of HCV infection among drug users who never inject drugs reported by van den Hoek et al. [9] (4 [10%] of 42 subjects), Gyarmathy et al. [10] (42 [12%] of 337 subjects), Fingerhood et al. [11] (50 [21%] of 241 subjects), and Santana Rodriguez et al. [8] (92 [35%] of 168 subjects). The data on route of drug administration were based on selfreporting. One must always consider the possibility that injection drug use was underreported and that some of the HCV infection among the NIDUs may have actually occurred through injection of drugs [18] [19] [20] . Although it is certainly possible that some of the NIDUs in this study may have injected drugs and become infected with HCV via injection of drugs, it does not appear that underreporting of injection drug use is a viable explanation for the results of the study. First, the wish to enter drug abuse treatment is not easily correlated with denial of drug injection. Certainly, participants would not have been denied any services simply because they admitted to injecting drugs. Second, the pattern of hepatitis infection among NIDUs was quite different from the pattern among IDUs in this study. Among the IDUs, the prevalence of HCV infection was much higher (82% among unvaccinated subjects) than the prevalence of HBV infection (68% among unvaccinated subjects). A higher prevalence of HCV infection than HBV infection is consistent with observations for almost all populations of IDUs [21] [22] [23] . In contrast, the prevalence of HBV infection was slightly higher (22% among unvaccinated subjects) than the prevalence of HCV infection (20%) among the NIDUs in this study.
The pattern of a higher prevalence of HBV infection than HCV infection among NIDUs was also observed in a New York study [10] , which found a 23% prevalence of HBV infection and a 12% prevalence of HCV infection among NIDUs. In the New York study, the duration of heroin use (15 years) and having been tattooed were associated with HCV seropositivity.
Although it is not possible to fully compare the results from the New York study with the results of the present study, there does appear to be considerable consistency across the 2 studies.
Presence of antibody to HBV was the best predictor of presence of anti-HCV among both NIDUs and IDUs in this study. This suggests that the modes of transmission of the 2 viruses were similar among all drug users, although the difference in the prevalences of HCV and HBV infection among the IDUs and NIDUs also suggests important differences in the frequency of transmission through various routes. Transmission through unprotected sexual activity may have occurred among the NIDUs in this study [3, 10] : of the 75 subjects in this group who declared that they had a stable sex partner, 27 (36%) had a partner with a history of or current drug use. It has been reported that practices such as tattooing and perhaps also piercing may be a route of HCV transmission [24] ; however, these possibilities were not analyzed in the present study. For noninjection drug use, transmission through the sharing of equipment, which could convey the virus to denuded nasal mucosa, may have occurred [25] . Moreover, the sharing of injecting equipment may not be reported, as described elsewhere [10] , and could be a means of transmission.
Studies of the incidence of HCV infection are needed to identify the relative probability of these possible routes of transmission. Social network factors, including the extent to which NIDUs associated with IDUs, should be included in such incidence studies.
There was an interesting difference in the prevalence of HCV infection among the very long-term (у10 years) IDUs and NIDUs. The prevalence of HCV infection among the long-term IDUs approached true population saturation. The prevalence of HCV infection among the long-term NIDUs, however, appeared to plateau at ∼40%. The reasons why the prevalence of HCV infection did not continue to increase with duration of drug use remain to be determined. Loss of HCV-positive patients to the population entering drug abuse treatment programs and possible changes in risk behavior are both possibilities. We note that there may be qualitative differences in exposure to HCV among IDUs (who are likely to have multiple exposures to HCV, including multiple exposures from the same source), persons who receive transfusions (who are likely to receive a very large infectious dose), and NIDUs (who are more likely to have infrequent exposure to small infectious doses). Natural history studies of the course of HCV infection among NIDUs would be of great interest.
The low percentage of NIDUs (12%) in this cohort is the normal proportion of NIDUs among the population of drug addicts in the geographical area of the study. The low percentage is an indication of, among other things, the truthful responses of interviewees, which, therefore, reflect the real prevalence of use of the injecting route.
HCV infection is a growing public health problem for NIDUs, as well as for IDUs. Additional research on HCV among NIDUs is urgently needed to develop scientifically based HCVprevention programs for NIDUs.
